|
Sign In to gain access to subscriptions and/or personal tools.
|
Multiple Sclerosis, Vol. 12, No. 6,
731-737 (2006)
DOI: 10.1177/1352458506070941
© 2006 SAGE Publications
Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients
C Gneiss
Clinical Department of Neurology, Innsbruck Medical University, 6020 Innsbruck, Austria
P Tripp
Clinical Department of Neurology, Innsbruck Medical University, 6020 Innsbruck, Austria
F Reichartseder
Clinical Department of Neurology, Innsbruck Medical University, 6020 Innsbruck, Austria
R Egg
Clinical Department of Neurology, Innsbruck Medical University, 6020 Innsbruck, Austria
R Ehling
Clinical Department of Neurology, Innsbruck Medical University, 6020 Innsbruck, Austria
A Lutterotti
Clinical Department of Neurology, Innsbruck Medical University, 6020 Innsbruck, Austria
M Khalil
Clinical Department of Neurology, Innsbruck Medical University, 6020 Innsbruck, Austria
B Kuenz
Clinical Department of Neurology, Innsbruck Medical University, 6020 Innsbruck, Austria
I Mayringer
Clinical Department of Neurology, Innsbruck Medical University, 6020 Innsbruck, Austria
M Reindl
Clinical Department of Neurology, Innsbruck Medical University, 6020 Innsbruck, Austria
T Berger
Clinical Department of Neurology, Innsbruck Medical University, 6020 Innsbruck, Austria
F Deisenhammer
Clinical Department of Neurology, Innsbruck Medical University, 6020 Innsbruck, Austria, florian.deisenhammer{at}uibk.ac.at
Interferon beta (IFNß) is a first-line therapy for multiple sclerosis (MS). However, some patients experience a decline in efficacy with continued therapy due to the development of anti-IFNß neutralizing antibodies (NAb). We investigated the frequency of NAb cross-sectionally in 846 MS patients who were receiving IFNß-1b, IFNß-1a im, or IFNß-1a sc. The frequency of NAb in patients receiving IFNß-1a im was lower (5%) than in patients treated with any other form of IFNß (22-35%) (P < 0.0001). Binding antibodies (BAb) were measured in 808 patients. The frequency differed significantly between treatment groups, ranging from 45% (IFNß-1a im) to 88% (IFNß-1b). The proportion of NAb-positive patients within the BAb-positive group differed significantly among treatment groups, ranging between 12% (IFNß-1a im) and 51% (IFNß-1a sc). The median NAb titer from all IFNß-1a-treated patients was higher than from IFNß-1b-treated patients (446 versus 171 NU/mL, P = 0.04). Among NAb-positive patients, the frequency of NAb titers > 100 NU/mL was 71% for IFNß-1a compared with 58% for IFNß-1b (P = 0.04). Except for conflicting data regarding IFNß-1a sc, the results are generally consistent with the literature and together with the differing proportion of NAb-positive patients within the BAb-positive group, provide further insight into the immunogeni-city of the IFNß preparations.
Key Words: antibody titer • IFNß-1a • IFNß-1b • myxovirus A bioassay • neutralizing antibodies • relapsing-remitting multiple sclerosis
References
- Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville Jet al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability . Brain 1989; 112: 133-146 .[Abstract/Free Full Text]
- Stuart WH, Cohan S, Richert JR, Achiron A. Selecting a disease-modifying agent as platform therapy in the long-term management of multiple sclerosis . Neurology 2004; 63: S19-S27 .[Abstract/Free Full Text]
- IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial . Neurology 1993; 43: 655-661 .[Abstract/Free Full Text]
- Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AMet al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) [see comments] . Ann Neurol 1996; 39: 285-294 .[CrossRef][ISI][Medline]
[Order article via Infotrieve][Published erratum appears in Ann Neurol 1996; 40: 480-480 ][ISI][Medline]
[Order article via Infotrieve]
- PRISMS. Randomised double-blind placebo-controlled study of interferon ß-1a in relapsing/remitting multiple sclerosis . Lancet 1998; 352: 1498-1504 .[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Giovannoni G, Munschauer F, Deisenhammer F. Neutralising antibodies to interferon beta during treatment of multiple sclerosis . J Neurol Neurosurg Psychiatry 2002; 73: 465-469 .[Free Full Text]
- The IFNB Multiple Sclerosis Study Group, The University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years . Neurology 1996; 47: 889-894 .[Abstract/Free Full Text]
- Rudick RA, Simonian NA, Alam JA, Campion M, Scaramucci JO, Jones Wet al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG) [see comments] . Neurology 1998; 50: 1266-1272 .[Abstract/Free Full Text]
- Francis GS, Rice GP, Alsop JC. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS . Neurology 2005; 65: 48-55 .[Abstract/Free Full Text]
- Kappos L, Clanet M, Sandberg-Wollheim M, Radue EW, Hartung HP, Hohlfeld Ret al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study . Neurology 2005; 65: 40-47 .[Abstract/Free Full Text]
- Rudick RA. Biologic impact of interferon antibodies, and complexities in assessing their clinical significance . Neurology 2003; 61: S31-S34 .[Abstract/Free Full Text]
- Sorensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtzen K, the Danish Multiple Sclerosis Study Group. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy . Neurology 2005; 65: 33-39 .[Abstract/Free Full Text]
- Gneiss C, Reindl M, Lutterotti A, Ehling R, Egg R, Khalil Met al. Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity . Mult Scler 2004; 10: 507-510 .[Abstract/Free Full Text]
- Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJet al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis . N Engl J Med 2000; 343: 898-904 .[Abstract/Free Full Text]
- Clanet M, Radue EW, Kappos L, Hartung HP, Hohlfeld R, Sandberg-Wollheim Met al. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS . Neurology 2002; 59: 1507-1517 .[Abstract/Free Full Text]
- Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon Beta 1a in MS (SPEC-TRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS clinical results . Neurology 2001; 56: 1496-1504 .[Abstract/Free Full Text]
- European Study Group on Interferon. Placebo-controlled multicentre randomised trial of interferon ß-1b in treatment of secondary progressive multiple sclerosis . Lancet 1998; 352: 1491-1497 .[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Grossberg SE, Kawade Y, Kohase M, Klein JP. The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit . J Interferon Cytokine Res 2001; 21: 743-755 .[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Kawade Y. An analysis of neutralization reaction of interferon by antibody: a proposal on the expression of neutralization titer . J Interferon Res 1980; 1: 61-70 .[ISI][Medline]
[Order article via Infotrieve]
- Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O’Connor Pet al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial . Neurology 2002; 59: 1496-1506 .[Abstract/Free Full Text]
- Bertolotto A, Malucchi S, Sala A, Orefice G, Carrieri PB, Capobianco Met al. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory . J Neurol Neurosurg Psychiatry 2002; 73: 148-153 .[Abstract/Free Full Text]
- Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi Aet al. Every-other-day interferon beta-1b versus once-weekly interferon beta- 1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN) . Lancet 2002; 359: 1453-1460 .[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Sorensen PS, Ross C, Clemmesen KM, Bendtzen K, Frederiksen JL, Jensen Ket al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis . Lancet 2003; 362: 1184-1191 .[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Polman C, Kappos L, White R, Dahlke F, Beckmann K, Pozzilli Cet al. Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b . Neurology 2003; 60: 37-43 .[Abstract/Free Full Text]
- Hay CR, Baglin TP, Collins PW, Hill FG, Keeling DM. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors’ Organization (UKHCDO) . Br J Haematol 2000; 111: 78-90 .[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- The Once Weekly Interferon for MS Study Group. Evidence of interferon ß-1a dose response in relapsingremitting MS . Neurology 1999; 53: 679-686 .[Abstract/Free Full Text]
- Ross C, Clemmesen KM, Svenson M, Sorensen PS, Koch-Henriksen N, Skovgaard GLet al. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group [In Process Citation] . Ann Neurol 2000; 48: 706-712 .[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Bertolotto A, Malucchi S, Milano E, Castello A, Capobianco M, Mutani R. Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations . Immunopharmacology 2000; 48: 95-100 .[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Deisenhammer F, Reindl M, Berger T. Immunoglobulin subclasses in patients with serum-binding and neutralizing antibodies against interferon-1b . J Interferon Cytokine Res 2001; 21: 167-171 .[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Mayr M, Berek K, Deisenhammer F. Evolution of interferon-beta binding antibodies in MS patients may predict development of neutralizing antibodies . Eur J Neurol 2003; 10: 462-464 .[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Cleland JL, Lam X, Kendrick B, Yang J, Yang TH, Overcashier Det al. A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody . J Pharm Sci 2001; 90: 310-321 .[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Retrieved 27 March 2006, from www.avonex.com/msav-Project/avonex.portal/_baseurl/threeColLayout/SCSRepository/en_US/avonex/includes/footer/prescribe_info_med_guide.xml
- Retrieved 27 March 2006, from www.rebif.com/assets/pdfs/Rebif_PI.pdf
- Giovannoni G. Strategies to treat and prevent the development of neutralizing anti-interferon-{beta} antibodies . Neurology 2003; 61: 13S-17S .[Abstract/Free Full Text]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
|
